I-Mab Enters Clinical Collaboration With Bristol Myers Squibb To Evaluate Claudin 18.2 x 4-1BB Bispecific Antibody Givastomig Combination; No Terms Disclosed

Author: Benzinga Newsdesk | June 05, 2024 07:02am

The collaboration will evaluate the combination of givastomig, an investigational Claudin 18.2 x 4-1BB bispecific antibody jointly developed by I-Mab and ABL Bio, with Bristol Myers Squibb's immune checkpoint inhibitor, nivolumab, and chemotherapy, as a potential first-line treatment for patients with advanced Claudin 18.2-positive gastric and esophageal cancers.

Under the terms of the agreement, the study will be a multi-national Phase 1 study conducted by I-Mab. Bristol Myers Squibb will supply nivolumab. Nivolumab is an immune checkpoint inhibitor that is designed to block the PD-L1 protein on cancer cells from binding to PD-1, enhancing T-cell function and resulting in improved anti-tumor responses.

Posted In: BMY IMAB